"Our leading drug candidate is OPT-302 and that will be used for the treatment of wet AMD. Wet AMD is the leading cause of blindness in the Western world in people over the age of 50 and it's a highly prevalent disease and I think we've got a very promising drug candidate here that we are developing...
Our technology at Opthea (ASX:OPT)
is based on intellectual property centered around members of a certain family of proteins, that are involved in controlling blood vessel development as well as vascular leakage. Our lead compound OPT-302 is a protein molecule we inject directly into the eye, and it's designed to very potently block two signals that control blood vessel development and cause vessels to leak.
What we are hoping to do by injecting that into the eye is to stop those processes and have an impact on the disease and loss of vision in those patients, as well as actually improve vision in those patients."